推荐产品
产品名称
CHIRAL-HSA 高效液相色谱柱, 5 μm particle size, L × I.D. 5 cm × 3 mm
物料
stainless steel column
质量水平
Agency
suitable for USP L79
产品线
CHIRALPAK®
包装
pkg of 1 ea
制造商/商品名称
CHIRALPAK®
参数
137 bar pressure (2000 psi)
20-30 °C temperature
40 °C max. temp.
技术
HPLC: suitable
长度 × 内径
5 cm × 3 mm
基质
fully porous particle
基质活性基团
human serum albumin phase
粒径
5 μm
工作pH值
2-8
分离技术
chiral
正在寻找类似产品? 访问 产品对比指南
一般描述
CHIRALPAK HSA, which uses human serum albumin as the chiral selector, is highly selective for acidic racemates, preferably weak and strong acids, zwitterionic and non-protolytic (neutral) compounds. Phosphate buffers (normally 0.01-0.1M, pH 5-7) with addition of organic modifiers are used as mobile phases. Enantioselectivity and retention can be regulated by changing the mobile phase composition. However, the primary use of CHIRALPAK HSA is for fast drug/protein binding studies (1). To calculate the % protein binding, measure the retention time of an unretained compound (t0) and the compound of interest (tr) on the CHIRALPAK HSA column. Then use the capacity factor equation:
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
k = (tr - t0)/tr
to calculate the % protein binding (P):
P = 100k/(k+1)
Different types of mobile phases can be used. A mobile phase consisting of 6% 2-propanol in 20 mM potassium phosphate buffer, pH 7.0 gives data in good agreement with literature data. The mobile phase conditions should be chosen to suit the drugs to be tested, i.e., for high protein binding drugs a mobile phase with higher eluting strength might be needed in order to reduce retention times.
(1) Goodman, A.; Gilman, A.G. The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill: New York, 1996; pp 1712-1792.
法律信息
CHIRALPAK is a registered trademark of Daicel Corp.
未找到合适的产品?
试试我们的产品选型工具.
法规信息
新产品
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门